Sarepta halts Duchenne gene therapy in some patients after second death

Sarepta Therapeutics reported a second patient death due to liver failure related to its Duchenne muscular dystrophy gene therapy, and said it’s suspending shipments of the treatment Elevidys for the subset of patients who can …